Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-10-11
|
dusquetide (SGX942) |
macrophage activation syndrome |
|
Soligenix (USA - NJ) |
Rare diseases |
2016-10-10
|
EC1169 |
metastatic castration-resistant prostate cancer (mCRPC) |
1 |
Endocyte (USA - IN) |
Cancer - Oncology |
2016-10-10
|
EC1456 |
non-small cell lung cancer (NSCLC) |
1 |
Endocyte (USA - IN) |
Cancer - Oncology |
2016-10-10
|
microcrystalline tyrosine (MCT) |
|
preclinical |
Allergy Therapeutics (UK) |
Technology - Services |
2016-10-10
|
vantictumab (anti-Fzd7, OMP-18R5) |
pancreatic cancer |
1 |
Bayer Healthcare (Germany) Oncomed Pharmaceuticals (USA) |
Cancer - Oncology |
2016-10-10
|
durvalumab (MEDI4736) and ISIS-STAT3Rx (AZD9150) or AZD5069 |
metastatic squamous cell carcinoma of the head and neck |
1-2 |
AstraZeneca (UK) |
Cancer - Oncology |
2016-10-10
|
ipafricept (OMP- 54F28 - Fzd8-Fc) |
advanced solid tumor cancers |
1b |
Bayer Healthcare (Germany) OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2016-10-10
|
PM01183 (lurbinectidin) |
breast cancer |
2 |
PharmaMar (Spain) |
Cancer - Oncology |
2016-10-10
|
RetinoStat® |
neovascular “wet” age-related macular degeneration (AMD) |
1 |
Oxford BioMedica (UK) |
Ophtalmological diseases |
2016-10-10
|
Prostvac® (rilimogene) and ipilimumab (Yervoy®) |
prostate cancer |
2 |
Bavarian Nordic (Denmark) University of California, San Francisco (UCSF) (USA - CA) |
Cancer - Oncology |
2016-10-09
|
Tecentriq® (atezolizumab) (MPDL3280A) |
non-squamous non-small cell lung cancer (NSCLC) |
3 |
Roche (Switzerland) |
Cancer - Oncology |
2016-10-09
|
Zykadia® - LDK378 (ceritinib) |
anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) |
2 |
Novartis (Switzerland) |
Cancer - Oncology |
2016-10-09
|
lirilumab or IPH2102/BMS-986015 in combination with nivolumab or Anti-PD-1 (BMS-936558) |
advanced solid tumors |
1 |
BMS (USA - NY) Innate Pharma (France) |
Cancer - Oncology |
2016-10-09
|
glembatumumab vedotin (CDX-011) |
unresectable Stage III or IV melanoma |
2 |
Celldex Therapeutics (USA - NJ) |
Cancer - Oncology - Rare diseases |
2016-10-09
|
Alimta® (pemetrexed) plus carboplatin in combination with Keytruda® (pembrolizumab) |
non-small cell lung cancer (NSCLC) |
1-2 |
Eli Lilly (USA - IN) Merck&Co (USA - NJ) |
Cancer - Oncology |
2016-10-09
|
nintedanib |
advanced colorectal cancer |
3 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2016-10-09
|
lirilumab or IPH2102/BMS-986015 in combination with ipilimumab (Yervoy®) |
advanced solid tumors (melanoma, non-small cell lung cancer - squamous and non-squamous histology, and castrate resistant prostate cancer) |
1 |
BMS (USA - NY) Innate Pharma (France) |
Cancer - Oncology |
2016-10-09
|
Opdivo® (nivolumab) |
stage IV or recurrent non-small cell lung cancer |
3 |
BMS (USA - NY) Ono Pharmaceutical (Japan) |
Cancer - Oncology |
2016-10-09
|
Giotrif® (afatinib) |
non-small cell lung cancer (NSCLC) |
3 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2016-10-09
|
Opdivo® (nivolumab) |
recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
3 |
BMS (USA - NY) Ono Pharmaceutical (Japan) |
Cancer - Oncology |